Affiliation:
1. Cedarville University , Cedarville, OH , USA
2. Trinity Health , Grand Rapids, MI , USA
Abstract
Abstract
Purpose
To provide an overview of the safety and efficacy, pharmacology, dosing, place in therapy, and clinical trials for tirzepatide, a novel glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist for treatment of type 2 diabetes.
Summary
Diabetes is a chronic disease state with a high burden on healthcare spending and patient quality of life. Incretin-influencing agents such as GLP-1 receptor agonists have gained favor as diabetes therapeutic options due to their impact on multiple glycemic factors as well as resulting weight loss and cardiovascular benefits. Tirzepatide was approved in 2022 for the management of type 2 diabetes and utilizes GLP-1 receptor agonism along with GIP agonism to simultaneously address 2 incretin pathways. Thus far, the SURPASS and SURMOUNT trials, for which findings have been published, have shown great efficacy of tirzepatide in glycosylated hemoglobin and weight reduction in multiple subgroup populations with and without diabetes. Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.
Conclusion
Tirzepatide is a novel agent on the market for type 2 diabetes management that offers targeting of a familiar pathway along with the new GIP pathway to address glycemic control in patients with diabetes. Tirzepatide is approved for use in patients with diabetes and may serve as a strong option for patients requiring improved glycemic and weight control.
Publisher
Oxford University Press (OUP)
Subject
Health Policy,Pharmacology
Reference49 articles.
1. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives;Reed;Diabetes Metab Syndr Obes,2021
2. 6. Glycemic targets: Standards of Medical Care in Diabetes-2021;American Diabetes Association;Diabetes Care,2021
3. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis;Norris;Am J Med,2004
4. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials;Sattar;Lancet Diabetes Endocrinol,2021
5. Anti-diabetic drugs and weight loss in patients with type 2 diabetes;Lazzaroni;Pharmacol Res,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献